In response to criticism that epilepsy care for children has little impact, healthcare professionals and administrators have developed various service models and strategies to address perceived inadequacies.
About Seizures: A seizure or convulsion can be a sudden, violent, uncontrollable contraction of a group of muscles. A seizure can also be more subtle, consisting of only a brief “loss of contact” or a few moments of what appears to be daydreaming.
The following list of medications are in some way related to, or used in the treatment of this condition.[…]
For the list of medications, Visit Site —> List of Seizures (Convulsions) Medications (60 Compared) – Drugs.com
A seizure-detecting smart band could help people with epilepsy notify their caregivers in the event of an emergency.
Embrace, a smart band created by Empatica, uses advanced machine learning (AI) to monitor seizures, collecting physiological data from users to try to detect unusual events such as convulsive seizures.
The Embrace band is paired to a smartphone or iPod via Bluetooth connection and works in tandem with the Alert app, which sends SMS and phone call alerts to selected caregivers when a seizure is detected.
Empatica CEO Matteo Lai said: “Embrace is a Medical Grade device in Europe and the only FDA-cleared seizure monitoring smart watch, which uses AI to monitor for the most dangerous kinds of seizures, known as ‘grand mal’ or ‘generalized tonic-clonic’ seizures, and send an alert to summon caregivers’ help.
“Embrace stands apart from any seizure detection system in that it measures multiple indicators of a seizure.
“Its unique property is its use of Electrodermal Activity, a signal used by stress researchers to quantify physiological changes related to sympathetic nervous system activity, also known as the ‘fight or flight’ response.”
When Embrace detects a seizure, it will send a command to the Alert app, which then sends an alert to the designated caregiver.
“Users can add caregivers who are notified in real time with a phone call and an SMS containing the wearer’s GPS location.
Lai said: “There is also another product that works with Embrace, a diary app called Mate, where the caregiver can monitor sleep and physical activity for patients wearing Embrace.
“The Mate app displays the seizures automatically detected by the Embrace and patients can also insert other, non-convulsive seizures that aren’t automatically detected.”
Morgan, a user of Embrace, said: “I purchased the Embrace mostly because my seizures have all happened during my sleep.
“I also purchased it so that I could regain a lot of the confidence that I lost once I was diagnosed with epilepsy.
“On November 6th 2016, I had a seizure(s) that lasted over 40 minutes. The Embrace detected the seizures and my emergency contacts were notified… I believe the Embrace saved my life. It helps give peace of mind to me, as well as my friends and family.
“Having the Embrace has also helped me regain the confidence to start being active again.”
Embrace costs 249 US dollars (£177), and is available from the Empatica website.
Epilepsy is not a disease, it is a disorder. People who have epilepsy are fully capable of leading a normal life. Read on to find out more…
Epilepsy is a neurological condition that is estimated to occur in 0.5% to 1% of the population of any country. According to the Department of Neurology, Jinnah Postgraduate Medical Centre, Karachi, one in every hundred Pakistani has epilepsy and at least 5 family members are affected in some way or the other due to it. The condition is also twice as common in rural areas as compared to the urban. Epilepsy is a sudden surge of electrical activity in the brain that causes a temporary disturbance in the messaging systems between the brain cells.
Unfortunately, the condition has been stigmatised in the country due to misinformation. Recently, a press conference was held in a bid to create awareness regarding epilepsy at Najumuddin Auditorium at Jinnah Postgraduate Medical Centre (JPMC) to squash the certain stereotypes of the disorder. According to Prof Dr Hasan Aziz, “It is a common misconception among unaware people that an epilepsy attack is a work of some ‘evil spirit’ or ‘supernatural beings’, or that person can be cured by sniffing a shoe. It is not contagious and is rarely hereditary; and it does not affect your intellectual capabilities. A person can live their life normally if they take their prescribed medicines on time, take care of their diet and sleep.”
There have been many famed personalities like Newton, Tolstoy, Socrates, Da Vinci, to our very own Abdul Sattar Edhi, Nadia Jamil and Suhaee Abro, who are epileptic.
Nadia Jamil, actress and mother of two young boys, was diagnosed with epilepsy in 2011, and has not let that get in the way of her work, “As an actress I need my body to work and as a mother I always have to be energetic. Initially, there was a sense of panic and the limitations of my body hit me, like it would for a person with asthma or diabetes. But, medications have helped me. I cook, clean, shop for groceries, ride a bicycle, work and run after my boys without fear. Epilepsy can be handled with medications and a little care in terms of lifestyle – getting proper rest and full sleep. To anyone who has epilepsy, you are not sick, there isn’t anything that you can’t accomplish. It’s not a disease, it is a condition which can be controlled if taken care,” stated Nadia Jamil while talking to this scribe.
According to National Epilepsy Centre (NEC) at JPMC, in about 70 per cent of the cases, there seems to be no obvious cause of the condition. However, for the remaining cases, strokes, brain tumours, head trauma (such as occurring during a car crash), infectious diseases (for example: AIDS), congenital abnormalities (prenatal injury, or brain damage that occurred before birth), or development disorders (such as autism or neurofibromatosis) are some of the factors that increase the risk of epilepsy.
The key symptom of epilepsy is repeated seizures. One should immediately consult a doctor if it is a recurring matter. A person may experience convulsions with no fever, short spells of blackout, fainting spells during which bowel and bladder isn’t in control. The person may do unexplainable things such as suddenly become stiff, have bouts of blinking or chewing, or do repetitive or jerking movements.
For diagnosis, a person goes through a complete physical and neurological exam, and their clinical history is taken along with a detailed account of their seizure that occurred. Additional testing may include EEG (Electroencephalogram) that detects the brain’s electrical activity.
The epileptic seizures can be controlled with antiepileptic drug (AED) therapy. The doctor will prescribe the dosage according to several factors for a particular individual like age, gender, overall health and the severity of the seizures. So, it is mandatory to take the prescribed dosage with punctuality.
In some cases, if there is an underlying brain condition that is causing these seizures, surgeries can be recommended. And, if the AEDs don’t work, the next step could be surgery.
While one is still trying to control their condition, it is imperative to take certain precautions. An epileptic person should avoid all activities that can potentially put their lives at risk like riding or driving a vehicle, working in factories (like having to operate heavy or open machinery) or heights. Anything that involves swimming, working near an open flame should be done under supervision.
There are also certain triggers that can provoke seizures in people with epilepsy like missing medications, consuming recreational drugs and alcoholic beverages, lack of sleep and other drugs that may interfere with the prescribed medicines.
Do not panic: If you witness someone having seizures, it’s important for you to stay calm in order to help someone.
Protect the person from potential injuries: Help keeping them from falling and gently guide them to the floor. Remove any objects or furniture that may injure the person.
Place a pillow under their head: If they are already on the ground, turn them to one side and loosen the clothing around their neck. Place something soft under their head.
Don’t force anything: Do not forcibly open or put anything in mouth (water, spoon, cloth). You may end up hurting them and yourself.
Record everything: Record the event on your device to show it to the doctor. Pay close attention to the body movement during seizure, how long it lasted, how the person reacted after and possible injuries.
Posted Mar 9 2018 in Anti-epileptic drugs
Approximately 60-70% of people with epilepsy will have their seizures controlled with medication. But even when epileptic seizures are controlled with medication the drugs used may have unpleasant, unwanted side effects. Ideally what patients and clinicians are looking for is a drug which works effectively and has no down side. Now new research from the Australian National University aims to look at the molecular level to find a way of reducing negative side effects without reducing the drug’s efficacy. If you would like to read more about this study please click on the link here:
A new class of epilepsy drugs based on a marijuana ingredient could be become available in the United States as early as the second half of 2018 pending approval from the Food and Drug Administration.
GW Pharmaceuticals, the maker of the drug called Epidiolex, announced on Wednesday the promising results of a clinical study of the drug.
A group of 171 individuals were randomly assigned to either receive Epidiolex treatment or placebo. The participants were between 2 and 55 years old with a condition called Lennox-Gastaut syndrome. They were also suffering from seizures existing drugs cannot efficiently control.
The participants on average had tried and discontinued use of six anti-seizure treatments and were experiencing 74 “drop” seizures per month. This particular seizure involves the entire body, head and trunk, and often leads to fall and other injuries.
Results of the study, which was reported in the journal Lancet, showed that over a period of 14 weeks, 44 percent of the patients taking the drug saw significant reduction in seizures. The rate is significantly higher compared with the 22 percent in the placebo group. More of those who were given the experimental drug also experienced a 50 percent or greater reduction in drop seizures.
“LGS is one of the most difficult types of epilepsy to treat and the majority of patients do not have an adequate response to existing therapies,” said Elizabeth Thiele, from Harvard Medical School. “These results show that Epidiolex may provide clinically meaningful benefits for patients with LGS.”
Adverse events associated with use of the drug include diarrhea, decreased appetite, sleepiness, vomiting, and fever. Once given the go-signal to be marketed in the United States, the drug is intended to be used as a prescription drug to be dispensed by doctors.
“Add-on cannabidiol is efficacious for the treatment of patients with drop seizures associated with Lennox-Gastaut syndrome and is generally well tolerated. The long-term efficacy and safety of cannabidiol is currently being assessed in the open-label extension of this trial,” investigators wrote in their report.
GW Pharmaceuticals has not yet disclosed the pricing of the drug, but Justin Gover, GW’s chief executive officer, said that the company is already in talks with health insurers about coverage.
Last Updated: February 14, 2018.
Both focused attention and progressive muscle relaxation result in reductions in seizure frequency in patients with epilepsy, according to a study published online Feb. 14 in Neurology.
Sheryl R. Haut, M.D., from the Montefiore Medical Center in Bronx, N.Y., and colleagues randomized 66 adults with medication-resistant focal epilepsy to 12 weeks of either PMR with diaphragmatic breathing or control focused-attention activity with extremity movements.
The researchers found that seizure frequency was reduced from baseline in both treatment groups (PMR: 29 percent; P < 0.05; focused attention: 25 percent; P < 0.05). There was no difference between the two interventions in seizure reduction (P = 0.38), although PMR was associated with greater stress reduction compared to focused attention (P < 0.05). Daily stress was not found to predict seizures.
“These findings highlight the need for larger, individually targeted behavioral therapy trials to control seizures and improve quality of life in patients with epilepsy,” the authors write.
The compound, valproate, is also used for migraine and bipolar disorder, and doctors already advised against prescribing the medicine for pregnant women in France.
Updated: Feb 10, 2018 13:45 IST
An expert committee of Europe’s medicines watchdog recommended Friday that a drug used to treat epilepsy and linked to malformations in children not be used in pregnancy. The compound, valproate, is also used for migraine and bipolar disorder, and doctors already advised against prescribing the medicine for pregnant women in France. France’s medicines regulator, known by the acronym ANSM, asked the London-based European Medicines Agency (EMA) to conduct a risk review.
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) said in a statement Friday it was recommending that valproate not be used by pregnant women for any of the three medical conditions. For women suffering from epilepsy, however, it may be impossible for some to stop after becoming pregnant, it said. These may have to continue treatment, though with “appropriate specialist care”. The experts also advised against prescribing the drug for women “from the time they become able to have children”, unless using contraception.
The interest in cannabis-based products for the treatment of refractory epilepsy has skyrocketed in recent years. Marijuana and other cannabis products with high content in Δ(9) –tetrahydrocannabinol (THC), utilized primarily for recreational purposes, are generally unsuitable for this indication, primarily because THC is associated with many undesired effects. Compared with THC, cannabidiol (CBD) shows a better defined anticonvulsant profile in animal models and is largely devoid of adverse psychoactive effects and abuse liability. Over the years, this has led to an increasing use of CBD-enriched extracts in seizure disorders, particularly in children. Although improvement in seizure control and other benefits on sleep and behavior have been often reported, interpretation of the data is made difficult by the uncontrolled nature of these observations. Evidence concerning the potential anti-seizure efficacy of cannabinoids reached a turning point in the last 12 months, with the completion of three high-quality placebo-controlled adjunctive-therapy trials of a purified CBD product in patients with Dravet syndrome and Lennox-Gastaut syndrome. In these studies, CBD was found to be superior to placebo in reducing the frequency of convulsive (tonic-clonic, tonic, clonic, and atonic) seizures in patients with Dravet syndrome, and the frequency of drop seizures in patients with Lennox-Gastaut syndrome. For the first time, there is now class 1 evidence that adjunctive use of CBD improves seizure control in patients with specific epilepsy syndromes. Based on currently available information, however, it is unclear whether the improved seizure control described in these trials was related to a direct action of CBD, or was mediated by drug interactions with concomitant medications, particularly a marked increased in plasma levels of N-desmethylclobazam, the active metabolite of clobazam. Clarification of the relative contribution of CBD to improved seizure outcome requires re-assessment of trial data for the subgroup of patients not comedicated with clobazam, or the conduction of further studies controlling for the confounding effect of this interaction. (2017;7:61-76) […]